This senior level appointment reflects CMR’s commitment to working closely with the clinical community to realise the untapped potential of robotic assisted minimal access surgery for surgeons and patients across the globe. The new appointment comes soon after the company recently announced hiring its 100th employee six months ahead of schedule.
Judi will be responsible for driving forward an evidence strategy that will support the company to realise its ambition.
Judi brings to CMR over 25 years’ experience in medical device and healthcare industries. She joins from Philips where she was Head of Quality, Regulatory, Clinical and Medical Affairs for Emerging Businesses, leading the development of regulatory and clinical strategies for market introduction of novel innovations.
Prior to Philips, Judi spent 15 years at Ethicon, part of the Johnson & Johnson Medical Device Group. With roles of increasing responsibility, Judi led the development and execution of global evidence strategies to address clinical and regulatory challenges with Class II & III medical devices, biologics and combination products, and served on the Global Management Board as VP, Clinical Research & Development.
Commenting on the appointment, Martin Frost, Chief Executive Officer, CMR said:
“Judi’s global outlook mixed with commercial and scientific expertise will be a real asset to our fast growing highly-skilled team. She brings invaluable experience from her years immersed in surgical research at some of the world’s leading global medical device companies. We’re thrilled to have her on board.”
Commenting on her new role, Judi Gauld, Head of Clinical and Medical Affairs, CMR said: “It’s really exciting to be part of a team with the potential to increase access to minimally invasive surgery for many more patients across the globe.
“Having previously worked for global companies, I am pleased to be part of this entrepreneurial, fast-moving British company that could be a real game changer in surgery.”
About CMR Surgical
CMR Surgical is a private, British, company developing the next-generation universal robotic system, Versius®, for minimal access (or “keyhole”) surgery.
The vision behind CMR is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics and addressing the six million people who still undergo open surgery each year.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.1
CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors. The Company achieved the registration of its Quality Management System to ISO 13485:2003 by Underwriters Laboratories LLC® (‘UL’), and the status as a UL Registered Firm, in September 2015.
For further information, please visit: https://cmrsurgical.com/
References
(1) Industry Forecast, Accuray Research
________________________________________________________